
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a prescriber's order for one patient. Not FDA-approved.
This is a compounded oral liquid containing tizanidine hydrochloride, prepared to a prescriber's order for one patient. Compounded preparations are not FDA-approved.
These listings cover every salt or ester form of each drug in the FDA National Drug Code Directory.
FDA-approved products containing tizanidine are listed in tablet, capsule and solution forms.
Liquid bases can be aqueous or nonaqueous, and USP <795> classifies the preparation by its water activity. Aqueous preparations carry shorter default beyond-use dates than nonaqueous ones. The date printed on the label is the one to follow.
Compounded drugs are not FDA-approved. This means that FDA does not review these drugs to evaluate their safety, effectiveness, or quality before they reach patients.
Tizanidine hydrochloride is a centrally acting muscle relaxant for spasticity, taken by mouth, that a pharmacy may compound when a prescriber orders it.
Tizanidine is a central alpha-2 adrenergic agonist, chemically related to clonidine. It is thought to reduce spasticity by increasing presynaptic inhibition of motor neurons in the spinal cord, which lowers muscle tone. Manufactured products are Zanaflex capsules and tablets, generic tizanidine capsules and tablets, and Ontralfy oral solution, all indicated for the treatment of spasticity in adults. MedlinePlus describes its use for muscle spasms and tightness caused by conditions such as multiple sclerosis and spinal injury. A 2024 review describes buccal, transdermal, nasal and rectal delivery systems for tizanidine that are still in development. A prescriber might order tizanidine compounded in a strength or form that is not manufactured, or in a vehicle free of a particular allergen or excipient. Compounded preparations are not FDA-approved and require a prescription.
Tizanidine labels carry no boxed warning. Do not use it with fluvoxamine or ciprofloxacin, strong CYP1A2 inhibitors that have caused large drops in blood pressure and heavy drowsiness, or if you have had an allergic reaction to tizanidine. Avoid other CYP1A2 inhibitors, including cimetidine, famotidine, certain heart rhythm drugs and oral contraceptives. It can cause low blood pressure and fainting, so rise slowly; liver injury; sedation, which alcohol and other sedatives increase; hallucinations; and allergic reactions. Stopping suddenly can cause rebound high blood pressure, fast heart rate and increased muscle tightness, so the dose is lowered gradually. Kidney or liver disease and older age raise the risk of side effects. The label says animal data suggest possible fetal harm. LactMed reports no information on breastfeeding and suggests watching the infant for drowsiness, weight gain and development. Talk to your prescriber or pharmacist about side effects.
Tizanidine is an imidazoline central alpha-2 agonist that reduces spinal motor neuron facilitation, with greatest effect on polysynaptic pathways; StatPearls notes it inhibits excitatory amino acid release from spinal interneurons. Per the Zanaflex label, oral absorption is essentially complete but absolute bioavailability is about 40 percent because of first-pass metabolism; about 95 percent is metabolized, mainly by CYP1A2, to inactive metabolites; the half-life is about 2.5 hours; and protein binding is about 30 percent. Capsules and tablets are bioequivalent fasting but not fed, so changing food status or dosage form can change exposure. Fluvoxamine raised AUC 33-fold and ciprofloxacin 10-fold. Clearance falls in older adults and by more than half with severe renal impairment. Labeled indication: spasticity in adults (Zanaflex capsules and tablets, NDA; Ontralfy oral solution, NDA). StatPearls lists off-label uses including chronic neck and low back pain, analgesic rebound headache and chronic migraine; these are not FDA-approved indications. Check aminotransferases at baseline and one month after reaching the maximum dose (label); monitor blood pressure before dose increases. Taper when stopping. Tizanidine is not a controlled substance (label). Dosing is per prescriber.
Shake the bottle if your label says to. Measure each dose with the oral syringe or dosing cup the pharmacy gave you, never a kitchen spoon. Give the liquid slowly into the mouth. Rinse the syringe with water after each use. Call the pharmacy if you are unsure how to measure.
Storage depends on the vehicle. Water-based liquids with a preservative usually carry a USP <795> beyond-use date of up to 35 days; without a preservative they are kept refrigerated for up to 14 days. Oil-based (nonaqueous) oral liquids may carry up to 90 days. Your label states whether to refrigerate and the beyond-use date. Keep out of reach of children and discard after that date.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Take orally